Related Experiment Videos
Cystic fibrosis and pulmonary involvement from multiple perspectives
1Department of Pediatrics, Hahnemann University, Philadelphia, PA 19102.
Seminars in Respiratory Infections
|September 11, 1992
Summary
Cystic Fibrosis (CF) research explores new therapies and improved drug delivery to combat lung disease. Advances in molecular genetics offer hope for a cure, increasing patient survival rates.
Area of Science:
- Pulmonary medicine
- Genetics
- Pharmacology
Background:
- Cystic Fibrosis (CF) primarily affects the lungs, with historical challenges in controlling disease progression.
- Current treatments face limitations in managing chronic inflammation and pulmonary decline.
Observation:
- Pulmonary involvement in CF is complex, influenced by over 200 genetic variations.
- Chronic inflammation and immune responses are significant factors in CF lung disease.
- Existing aerosol delivery methods require improvement for advanced therapies.
Findings:
- Numerous novel therapies are under development, including anti-inflammatories, protease inhibitors, and gene/cell-based treatments.
- Molecular genetics progress is rapidly advancing, potentially leading to curative strategies for CF.
- Patient survival has steadily increased, reaching 29.4 years in 1991, indicating treatment efficacy.
Implications:
- Enhanced aerosol delivery systems are crucial for novel therapeutic modalities.
- Further research into immune modulation and supportive care like lung transplantation is vital.
- Continued progress in molecular genetics and cell electrophysiology holds promise for a definitive cure for Cystic Fibrosis.